Haleon has announced plans to establish its first manufacturing facility in India, a state-of-the-art greenfield site at Pithampur, Madhya Pradesh. Spread across more than 40 acres in the Smart Industrial Park, the facility marks a significant investment in India’s consumer health sector and reinforces Haleon’s long-term commitment to the country as a strategic growth market.
The announcement was made in the presence of Dr Mohan Yadav, Chief Minister of Madhya Pradesh; Brian McNamara, Chief Executive Officer, Haleon; Kedar Lele, CEO India and President India Subcontinent, Haleon and Namrata Patel, Chief Supply Chain Officer, Haleon.
The new manufacturing site will serve as a key enabler for Haleon’s growth in India, strengthening supply chain resilience, driving domestic value addition, and supporting exports to wider Asia.
The facility is projected to create up to 500 jobs, along with indirect employment opportunities, with a strong focus on leveraging skill development, local talent, and supplier ecosystems. Haleon also aims to build a diverse and inclusive workforce, including an ambition of up to 30% women employees at the site.
Announcing the investment, Brian McNamara, CEO, Haleon, said, “India is a key strategic market for Haleon and an important driver of our long-term growth. This investment strengthens our local manufacturing footprint and expands our reach in one of the world’s fastest-growing consumer health markets. We aim to expand access to better everyday health for more than 300 million additional consumers in India. This will be key to achieving our broader ambition to reach one billion more consumers globally by 2030.”
Kedar Lele, CEO India and President, Haleon ISC, added, “Our investment in this new site will bring us closer to consumers, strengthen access to our brands, and support sustainable long-term growth. We are grateful for the strong partnership and support from the Government of Madhya Pradesh and Madhya Pradesh Industrial Development Corporation (MPIDC) in enabling this investment.”
The facility is designed on Haleon’s new global advanced blueprint and is set to feature future-ready automated manufacturing capabilities. It is expected to be operational by 2029–30, enabling Haleon to meet growing demand across domestic and international markets.
Rooted in Haleon’s purpose to deliver better everyday health with humanity, this investment reinforces the company’s commitment to making quality oral health solutions more accessible. Within this, Sensodyne has played a key role in India’s oral health journey for over a decade, helping millions understand and take better care of their oral health needs.
